Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies. (PubMed, Exp Ther Med) - Sep 11, 2026 - "Clinical outcomes varied by mutation subtype and EGFR-TKI regimen; relatively favorable progression-free survival (PFS) was observed with dacomitinib in L861Q and with afatinib- or dacomitinib-based treatment in selected S768I compound mutations. Exploratory Spearman analysis suggested that lower docking scores and more negative MM-GBSA ∆G_bind values were associated with longer PFS. These findings provide hypothesis-generating evidence that molecular simulation may help inform personalized EGFR-TKI selection for non-classical EGFR mutations, although validation in larger, consecutive and prospective multicenter cohorts is required."
Clinical data • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|
|
Chang Li; Fang Wei; Ge Gao; Nan Li; Niu Niu; Yan Wang
|